adults using the Prescribing Information System (PIS), a national prescribing and dispensing database for Scotland.

Methods For more than 95% of the dispensed prescriptions in primary care between December 2009 and November 2011 a valid patient identifier was available and the database includes some socio-demographical characteristics (age-group, sex, SIMD) of the patients. Data were also linked to hospital admission data. The analysis was limited to patients aged up to 44 years to reduce contamination by COPD.

Data

We identified 358,804 patients with 2,809,563 dispensed prescriptions for inhaled therapies used for asthma; equating to a prevalence of 11.4% of the 3,139,356 people aged 0–44 registered with a GP in Scotland. The age specific prevalence rates are detailed in the table. However, 95,207 patients had only one or two dispensed prescriptions for short-acting beta2-agonists (SABA) and no other inhaled therapies in the two years; we consider these patients to be unlikely to have active asthma (table). Additionally, 1,041 cases on inhaled therapy had hospital admission(s) with a diagnosis of COPD (ICD10: J40-J44) and are excluded from further analysis. 6,056 (2.3%) of people collecting inhaled therapy (>2 SABA) had at least one hospital admission with a primary diagnosis of asthma.

18.4% of patients collected SABA only, 46.8% collected SABA + inhaled corticosteroids (ICS), 0.1% (371) collected SABA + long acting beta2 agonist (LABA) only, 13.6% collected SABA + combined ICS/LABA preparation, 2.1% collected SABA + ICS + LABA, 1.7% collected ICS/LABA only, leukotriene receptor antagonists (LTRA) were collected by 8.1% and long acting antimuscarinic agents (LAMA) were collected by 1.0%.

Conclusion This current and whole population database indicates that the prevalence of asthma is approximately 10% in young adults and 15% in children living in Scotland but prevalence of active asthma is approximately 8% in adults and 10% in children.

Abstract P275 Table 1 Dispensed inhaled therapy and hospital admission data from the Scottish NHS databases

Age groups	Population	Inhaled therapy(n)	Prevalence %	>2 SABA and/or other (n)	Prevalence of active asthma
0–4	289,464	45,223	15.6	25,041	8.7%
5–14	572,289	76,018	13.3	56,223	9.8%
15–24	713,676	73,446	10.3	53,985	7.6%
25–44	1,563,926	164,117	10.5	128,348	8.2%
Total	3,139,356	358,804	11.4	263,597	8.4%

P276

THE IMPACT OF THE OPTIMUM PATIENT CARE SERVICE ON OUTCOMES FOR ADULT ASTHMATIC PATIENTS

doi:10.1136/thoraxjnl-2012-202678.368

¹D Ryan, ²F Ryan, ³L Mascarenhas, ³D Saralaya, ⁴M Britton, ²J von Ziegenweidt, ²A Burden, ²C Hutton, ²S Gould, ⁵P David. ¹Woodbrook Medical Centre, Loughborough, United Kingdom; ²Research in Real Life, Cambridge, United Kingdom; ³Bradford Teaching Hospital, Bradford, United Kingdom; ⁴St Peter's Hospital, Chertsey, United Kingdom; ⁵University of Aberdeen, Aberdeen, United Kingdom

Introduction and Objectives The Optimum Patient Care (OPC) service provides a comprehensive asthma assessment, analysing

both GP-recorded and patient-reported outcomes to generate patient-specific management recommendations (based on British guidelines) for considerations by practise staff. This study evaluates the effect of the OPC asthma service evaluation on real-life asthma control outcomes in a UK primary care adult asthma population compared with a control population.

Methods Routine and patient-reported questionnaire data were collected for 2952 patients with clinician-diagnosed asthma and 1 year outcome data managed in practises across Surrey and Leicester County and Rutland Primary Care Trusts. The effect of the OPC service was evaluated by assessing change in markers of asthma control between initiation and re-assessment: exacerbation frequency (Read code defined acute exacerbations and number of courses of acute oral steroids in previous 12 months) and risk status (high risk: ≥ 2 annual exacerbations). The number of OPC management suggestions implemented by each practise was also considered. Change in exacerbations over the 12 month period was compared with a control group of patients from UK practises who did not receive OPC management recommendations. Exacerbation rate ratios (RR) for treatment group were produced (relative to control), adjusted for baseline confounders (95%CI).

Results There were 2952 patients in the study from 22 practises. At time of re-assessment 10% of OPC management suggestions had been implemented and 22% of patients managed at British Thoracic Society (BTS) steps 4/5 had improved their risk status. 17.1% of patients in the control group (n=22,952) suffered from ≥ 1 exacerbation during the baseline year, increasing to 17.3% of patients after 12 months. For patients receiving the OPC management review, 24.8% had ≥ 1 exacerbation during baseline, decreasing to 15.3% following review.

Conclusions OPC's combined patient-reported and practise data assessment allowed thorough patient assessment and the generation of tailored management recommendations. Although only 10% of recommendations were implemented at 12 months, the OPC service appeared to have a beneficial effect on risk status and exacerbation rates.

Abstract P276 Table 1 Rate Ratios for treatment group exacerbations, compared to control of patients not receiving the OPC management review service.

Exacerbations	Control	Management review service
RR adjusted for age, baseline exacerbations	1.00	0.74 (0.66, 0.83)
RR adjusted for age, asthma management stage	1.00	0.76 (0.68, 0.85)

P277

STATE OF THE UNION - AN ASSESSMENT OF CURRENT ADULT ASTHMATICS, THEIR DEMOGRAPHICS, TREATMENT AND OUTCOMES IN 210 PRACTISES ACROSS THE UK

doi:10.1136/thoraxjnl-2012-202678.369

¹D Price, ²F Ryan, ²L Mascarenhas, ²D West, ²S Gould, ²C Hutton, ³D Ryan. ¹University of Aberdeen, Aberdeen, United Kingdom; ²Research in Real Life, Cambridge, United Kingdom; ³Woodbrook Medical Centre, Loughborough, United Kingdom

Abstract P277 Table 1 Asthma control and number of exacerbations per patient by BTS asthma management step

		Asthma Control n(%)			Total	Exacerbations		Total (≥ 1 exac.)
		Controlled	Partially Controlled	Uncontrolled		1	2+	
BTS stage	1	4081(27.1)	9202(61.2)	1754(11.7)	15037(100)	1166(7.8)	453(3)	1619(10.8)
	2	4221(18.8)	13888(61.9)	4329(19.3)	22438(100)	2299(10.2)	706(3.1)	3005(13.4)
	3	4136(17)	14665(60.1)	5589(22.9)	24390(100)	3357(13.8)	1826(7.5)	5183(21.3)
	4	1849(10.8)	9841(57.5)	5432(31.7)	17122(100)	2868(16.8)	2729(15.9)	5597(32.7)
	5	110(10)	614(56)	373(34)	1097(100)	80(7.3)	168(15.3)	248(22.6)